22 results about "Integrin binding" patented technology

The present invention relates to application of 64Cu in radionuclide-based cancer therapy in humans. More specifically, the invention relates to 64Cu labeled conjugates for use in the treatment of cancer patients including 64Cu labelled Integrin αVβ3 binding conjugates, such as [64Cu]NODAGA-E[c(RGDyK)]2.

A composition and method comprising an antibody that binds to integrin α3β1 are provided.

The application discloses an integrin-reformed specific heart and muscle targeting AAV9 dominant mutant. The application provides an adeno-associated virus capsid protein, which comprises a targeting peptide containing an amino acid sequence as shown in any one of SEQ ID NO: 1-28. According to the RGD sequence binding with integrin, the polypeptide specific binding principle, the random amino acid carrying and the construction of the diversified AAV capsid library, and the high-throughput screening of the AAV with the suitable capsid structure, the application successfully obtains a new adeno-associated virus vector with high heart and / or muscle transduction efficiency, and the new adeno-associated virus vector exhibits better heart and / or skeletal muscle targeting and transduction efficiency in an animal model, and the off-target expression in non-target tissues is significantly reduced, and the new adeno-associated virus vector has important scientific value and commercial prospect.

The invention relates to a ligand targeting neutrophil and neurons as well as a preparation method and application of the ligand. The ligand for targeting the neutrophil and the neuron is prepared from the following raw materials in parts by weight: 30 to 50 parts of DSPE-PEG-Tet1, 2 to 3 parts of ketal thiol with carboxyl groups at two ends and 30 to 50 parts of a neutrophil targeting ligand, the neutrophil targeting ligand is one or more of sialic acid, an anti-CD66b antibody, an anti-CD177 antibody, an anti-CD16b antibody, N-formylmethionine peptide (fMLF) and an analogue thereof, a CXCR1 / CXCR2 binding peptide, an integrin binding peptide, a selectin ligand and lectin. According to the invention, sequential targeting of neutrophile granulocytes-neurons can be realized, target cells of ischemic lesions can be accurately protected, and the improvement effect on the cerebral infarction area of MCAO rats can be obviously enhanced.

Provided is a cell scaffold material that improves the efficiency of introducing molecules into cells.　A cell scaffold material according to the present invention is for introducing molecules into cells, and contains a peptide-containing resin (A) having a synthetic resin part and a peptide part. The peptide part has a first peptide part and a second peptide part. The first peptide part and the second peptide part have different amino acid sequences. The first peptide part can bind to a first integrin, and the second peptide part can bind to a second integrin.

Described herein are fusion proteins which include factor H functional domains and may include VHH domains and integrin binding domains, and the use of such fusion proteins in methods of treatment of focal segmental glomerulosclerosis.

The present invention belongs to the field of pharmaceutical chemistry, and relates to an N-(benzoyl)-phenylalanine compound used as an α4β7 integrin antagonist, including the pharmaceutical composition and the use, and in particular to a compound represented by general formula (1). The compound exhibits good α4β7 integrin binding inhibitory activity, can be used as a high-efficiency α4β7 integrin antagonist, and used for preventing and / or treating α4β7 integrin-related diseases such as autoimmune diseases and inflammatory diseases.

The invention belongs to the technical field of gene engineering, and discloses recombinant human fibronectin as well as a preparation method and application thereof. The amino acid sequence of the recombinant human fibronectin disclosed by the invention is as shown in SEQ ID NO. 1. The recombinant human fibronectin comprises three fragments which are derived from natural fibronectin and have high hydrophilicity and multiple integrin binding capacity, the fragments are expressed in escherichia coli, and the recombinant human fibronectin with high soluble expression quantity is obtained; the recombinant human fibronectin has high activity of promoting proliferation and migration of human keratinocytes, and has potential application prospects in the aspects of skin repair and wound healing.

The invention provides a molecular self-assembly integrin patch for regulating and controlling mechanical signals of cells as well as a preparation method and application of the molecular self-assembly integrin patch, and an extracellular matrix (ECM) bionic cell patch is constructed through a molecular self-assembly technology. According to the patch, a laminin-derived integrin binding ligand is extended and self-assembled through an N-terminal aromatic amino acid to form a fibrous nano network, and the patch has controllable nano-scale ligand distribution, network viscoelasticity and stability, and can specifically activate integrin beta1 at the top end of MSC (mesenchymal stem cell), so that a mechanical signal is conducted from a cell membrane to a cell nucleus. The process coordinates cytoskeleton reconstruction, nuclear deformation and chromatin rearrangement, and finally drives the MSC to efficiently differentiate into neuron-like cells under the condition of no exogenous gene or chemical induction, so as to express nerve markers such as TUBB3 and present functional characteristics such as spontaneous calcium transient. The cell patch can be widely applied to nerve regeneration, tissue engineering, disease model construction and intelligent biological material development.

To provide an alpha (v) beta (6) integrin (avb6) binding polypeptide.SOLUTION: Disclosed herein are alpha (v) beta (6) integrin (avb6) binding polypeptides and their use in the treatment and detection of tumors and in the treatment of pulmonary fibrosis. In one aspect, a polypeptide comprising a specific amino acid sequence is disclosed, wherein the polypeptide binds to alpha (v) beta (6) integrin (avb6). In one embodiment, the amino acid residue at position 8 is R, the amino acid residue at position 9 is G, and the amino acid residue at position 10 is D.SELECTED DRAWING: Figure 3

A transkingdom platform for the delivery of therapeutics to target cells. The system maintains the export and uptake functions of Inv while modifying its targeting away from β1 integrin to other proteins expressed on the surface of target eukaryotic cells (i.e., a cell surface protein) or chemical moieties (i.e., a cell surface chemical moiety) expressed on the surface of a target eukaryotic cell by replacing D4 and D5 of Inv with a binding domain from a heterologous protein via genetic engineering. These heterologous proteins could be derived from bacterial, fungal, animal, or viral genomes. This engineering would result in the construction of a chimeric Inv protein in which D1-D3 (i.e., the non-binding domains) are fused in frame to an alternative binding domain derived from a heterologous protein. The alternative binding domain would interact with a different cell surface protein or chemical moiety, which can in some instances be referred to as a receptor, on the surface on the surface of a eukaryotic cell, thereby allowing specific targeting to cells independent of Inv's intrinsic β1 integrin binding.

This invention relates to the field of biomimetic nanozymes and their preparation technology, disclosing a biomimetic nanozyme, its preparation method, and its applications. A peptide-functionalized biomimetic nanozyme (HRPL) is obtained by loading rapamycin onto HMPB nanozymes, coating the surface with a platelet membrane, and functionalizing it with the integrin-binding peptide LXW7. The binding of the platelet membrane to the LXW7 peptide enables targeted delivery to the site of endothelial injury, promoting endothelial repair and re-epithelialization. In an acidic inflammatory microenvironment, HRPL releases rapamycin, inhibiting smooth muscle cell proliferation and migration, and preventing restenosis. HRPL also scavenges reactive oxygen species, reducing oxidative stress and local inflammation, thereby improving the vascular microenvironment. The therapeutic effect was evaluated using a typical rat carotid balloon injury model. This dual-targeting mechanism not only promotes endothelial repair but also reduces restenosis and inflammation, showing significant clinical therapeutic potential. Especially after stent implantation, HRPL helps improve prognosis, reduce complications, and restore vascular homeostasis.

A composition and method for the selective degradation of integrins, for example, used in the treatment of fibrosis, is provided. The compound of interest is a bifunctional integrin degradation molecule comprising a TG2 binding moiety linked to an integrin binding moiety.

Provided is a cell scaffold material that can bring about good maintenance of memory T cells and good T cell proliferation.　A cell scaffold material according to the present invention is used for culturing a cell population containing T cells and contains a peptide-containing resin (A) having a synthetic resin part and a peptide part. The peptide part has a first peptide part and a second peptide part. The first peptide part and the second peptide part have different amino acid sequences. The first peptide part can bind to a first integrin, and the second peptide part can bind to a second integrin. The dispersive component γd of the surface free energy of the cell scaffold material is at least 24.5 mJ / m2 and not more than 45.0 mJ / m2, and the dipole component γp of the surface free energy of the cell scaffold material is at least 1.0 mJ / m2 and not more than 20.0 mJ / m2.

The invention discloses a pathological blood-brain barrier targeting nano preparation for treating Alzheimer's disease and a preparation method thereof, and belongs to the technical field of biological medicines.The nano preparation takes nanoparticles formed by assembling amphiphilic block copolymers as a carrier, RAP peptide and RGD peptide are co-modified on the surface of the carrier, and the nano preparation is prepared. The RAP peptide can specifically recognize and combine with an RAGE receptor highly expressed by vascular endothelial cells in a pathological state, so that precise targeting is realized, and the RAP peptide also has the activity of blocking an RAGE-AB pathological pathway; the RGD peptide serves as an integrin binding motif, the endocytosis efficiency of the nanoparticle can be remarkably enhanced through the interaction with a cell surface integrin receptor, transfer of the nanoparticle to lysosome after endocytosis is promoted, and through the synergistic effect of the two ligands, the nanoparticle can be efficiently targeted to lesion cerebrovascular endothelium expressing RAGE and can also be efficiently targeted to the lesion cerebrovascular endothelium expressing RAGE. The RAGE protein can be effectively internalized and guided to the lysosome, so that the degradation of the RAGE protein is enhanced by virtue of a lysosome way while the targeted drug delivery is realized, and the active intervention on a key pathological pathway is realized.

Compounds, pharmaceutical compositions, and a method of treating hard tissue diseases and disorders are disclosed. The compounds may be a peptide and is structured to bind integrin αvβ3 expressed by osteocytes and by selective binding to the cell surface integrin on hard tissue forming cells regulate three-dimensional bone shape, cartilage formation and repair.

The present invention provides cyclic peptides comprising at least one non-canonical amino acid, which are capable of binding to αvβ6-integrin. Further provided are conjugates, building blocks, and uses thereof, as well as synthetic intermediates and methods for manufacturing the same.

Compositions and methods for selective degradation of integrin are provided, which are useful, for example, in the treatment of fibrosis. A compound of interest as a bifunctional integrin degrading molecule comprises a TG2 binding moiety linked to an integrin binding moiety.

Alpha(v) beta (6) integrin (avb6) binding polypeptides are disclosed herein, and their use in treating and detecting tumors, and their use in treating pulmonary fibrosis.

The invention provides, inter alia, methods of reducing gastrointestinal immune-related adverse events, such as colitis and diarrhea, in subjects undergoing an immune treatment, such as an immune oncology treatment, such as anti-CTLA4 antibody and anti-PD-1 antibody combination treatment for melanoma. In certain aspects, the methods encompass administering a therapeutically effective amount of a polypeptide that inhibits MAdCAM-integrin binding, such as an anti-α4β7 integrin antibody, such vedolizumab or a related antibody.

The application discloses a pathological blood-brain barrier targeting nano-preparation for treating Alzheimer's disease and a preparation method thereof, and belongs to the technical field of biological medicine. The nano-preparation takes nanoparticles assembled by an amphiphilic block copolymer as a carrier, and is co-modified with RAP peptides and RGD peptides on the surface. The RAP peptides can specifically recognize and bind to the RAGE receptor which is highly expressed by vascular endothelial cells in a pathological state, so that precise targeting is realized, and the RAP peptides also have the activity of blocking the RAGE-AB pathological pathway. The RGD peptides serve as an integrin binding motif, can significantly enhance the endocytosis efficiency of the nanoparticles through the interaction with the cell surface integrin receptor, and promote the transportation of the nanoparticles to lysosomes after endocytosis. Through the synergistic effect of the two ligands, the nanoparticles can not only be efficiently targeted to the diseased brain vascular endothelium expressing RAGE, but also be effectively internalized and guided to lysosomes, so that the targeted drug delivery is realized, the degradation of the RAGE protein is enhanced by means of the lysosome pathway, and the active intervention on the key pathological pathway is realized.